Back to Results
First PageMeta Content
Immunology / Autoimmune diseases / Biology / Treatment of multiple sclerosis / Genzyme / Alemtuzumab / Interferon beta-1a / Sanofi / Interferon / Multiple sclerosis / Cytokines / Immune system


Document Date: 2014-02-11 13:33:19

Open Document

File Size: 199,44 KB

Share Result on Facebook

City

Multiple Sclerosis Cambridge / New York / Paris / /

Company

EMD Serono Inc. / Bayer / Genzyme Corporation / Sanofi company / Sanofi-Aventis / /

Country

United States / Canada / Australia / Mexico / /

Event

FDA Phase / Company Listing Change / /

Facility

University of Guadalajara / /

IndustryTerm

Treatment of Multiple Sclerosis / therapeutic solutions / consumer healthcare / healthcare / pharmaceutical / diabetes solutions / /

MedicalCondition

MS disease / rare and debilitating diseases / rare diseases / disease / inflammatory process / leukopenia / serious infections / diabetes / active disease / multiple sclerosis / lymphopenia / MS / infections / /

MedicalTreatment

intravenous infusion / /

Organization

FDA / Department of Neuroscience / European Union / University of Guadalajara / /

Person

David Meeker / Miguel A. Macias / /

Position

President and CEO / integrated global healthcare leader / /

Product

Lemtrada / Rebif / Mexico / United States / Lemtrada® / /

ProvinceOrState

Mississippi / Massachusetts / /

Technology

Neuroscience / therapeutic solutions / /

URL

www.genzyme.com / /

SocialTag